Trius Confident After Phase II Results Against Skin Infections That Include MRSA
This article was originally published in The Pink Sheet Daily
Executive Summary
Torezolid, a second generation oxazolidinone antibiotic, is set to enter Phase III trials in early 2010 with unambiguous regulatory guidance, CEO says.
You may also be interested in...
Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints
Tedizolid, a next-generation antibiotic from the same class as Pfizer’s Zyvox, has met all complicated skin infection endpoints for both a U.S. and European filing, and Trius plans submissions in second half 2013 and first half 2014, respectively. European partnering talks, meanwhile, have gained new intensity.
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area